Recombinant DNA Advisory Committee - 12/2-3/93 
Others: 
Paul Aebersold, Food and Drug Administration 
Robert Anderson, Food and Drug Administration 
W. French Anderson, University of Southern California 
Briget Binko, Cell Genesys, Inc. 
Andrew Braun, Harvard University 
G'dali Braverman, ActUp 
Joe Bruder, GenVec, Inc. 
George Buffleben, Public 
Gracia Buffleben, Public 
Jeffrey Carey, Genetic Therapy, Inc. 
Rachel Carle, Genzyme Corporation 
Mike Casey, Genetic Therapy, Inc. 
Fred Chang, University of Michigan Medical Center 
Henry Chang, Shared Medical Research Foundation 
Jan Chapell, Genetic Therapy, Inc. 
Seng Cheng, Genzyme Corporation 
Yawen Chiang, Genetic Therapy, Inc. 
Larry Couture, Genzyme Corporation 
Ronald Crystal, New York Hospital/Cornell Medical Center 
Aileen Deist, Genetic Therapy, Inc. 
Anne Driscoll, Fox, Bennett, and Turner 
Eli Embley, F-D-C Reports, Inc. 
Habib Fakhrai, San Diego Cancer Research Institute 
Susan Falen, Genetic Therapy, Inc. 
Jeffrey Fox, ASM News and Biotechnology 
Joyce Frey, Food and Drug Administration 
Ray Frizzell, University of Alabama, Birmingham 
Morgan Gale, Hearings-on-the-Line 
Alan Goldhammer, Biotechnology Industry Organization 
Scott Graham, University of Iowa 
Adam Grossman, ProTravel International 
Lisa Grossman, ProTravel International 
Robert Grossman, ProTravel International 
Richard Haubrich, University of California, San Diego Treatment Center 
Douglas Hickman, T. Rowe Price 
David Holzman, BioWorld 
Tom Horiagon, Chimerix Corporation 
Edie Irvine, Genetic Therapy, Inc. 
Burkhard Jansen, University of Vienna 
Jack Jaugstetter, Genentech, Inc. 
Rachel King, Genetic Therapy, Inc. 
Toshi Kotani, Genetic Therapy, Inc. 
John Kovach, Mayo Clinic 
Imre Kovesdi, GenVec, Inc. 
Recombinant DNA Research, Volume 18 
[515] 
